Funds holding JADE BIOSCIENCES INC
ISIN US0080642061 · United States
- Fund holders
- 108
- Of which ETFs
- 17 91 other funds
- Value held
- 187.8M $
- Share of capital
- 16.2 % of 63.6M shares on Aug 3, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Russell 2000 Fund Rydex Series Funds | 72 | 1K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 58 | 1.4K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 47 | 697 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 43 | 604.2 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 13 | 192.8 $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 8 | 112.4 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Total Equity Markets ETF American Century ETF Trust | 5 | 74.2 $ | 0.00 % | as of Feb 28, 2026 ↗ | |
| Nuveen Life Stock Index Fund TIAA-CREF Life Funds | 5 | 70.3 $ | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 1.20 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 1.15 % | as of Apr 30, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.32 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright SmallCap Momentum ETF Invesco Exchange-Traded Fund Trust II | 0.31 % | as of Feb 28, 2026 ↗ |
| Fidelity Stock Selector Small Cap Fund Fidelity Capital Trust | 0.24 % | as of Apr 30, 2026 ↗ |
| Fidelity Series Small Cap Opportunities Fund Fidelity Securities Fund | 0.24 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Health Care Fund Fidelity Advisor Series VII | 0.24 % | as of Apr 30, 2026 ↗ |
| Fidelity Fundamental Small-Mid Cap ETF Fidelity Covington Trust | 0.17 % | as of Apr 30, 2026 ↗ |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 0.15 % | as of Apr 30, 2026 ↗ |
| Fidelity Small Cap Growth K6 Fund Fidelity Securities Fund | 0.13 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 108 | +11 | 10,292,251 | +8.1 % |
| 2026Q1 | 97 | +8 | 9,524,663 | +21.3 % |
| 2025Q4 | 89 | +14 | 7,849,617 | +35.0 % |
| 2025Q3 | 75 | +63 | 5,812,674 | +90,985.2 % |
| 2025Q2 | 12 | 6,382 |
Institutional managers
113 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 7,085,423 | 99.6M $ | as of Mar 31, 2026 |
| Fairmount Funds Management LLC | 4,553,494 | 64M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 3,671,083 | 51.6M $ | as of Mar 31, 2026 |
| Bellevue Group AG | 3,501,502 | 49.2M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 3,220,364 | 45.2M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 3,105,669 | 43.6M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 2,313,949 | 32.5M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 1,641,137 | 23.1M $ | as of Mar 31, 2026 |
| Remedium Capital Partners, LLC | 1,577,750 | 22.2M $ | as of Mar 31, 2026 |
| Versant Venture Management, LLC | 1,525,820 | 21.4M $ | as of Mar 31, 2026 |
| Avidity Partners Management LP | 1,400,708 | 19.7M $ | as of Mar 31, 2026 |
| SAMSARA BIOCAPITAL, LLC | 968,798 | 13.6M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 964,462 | 13.6M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 944,776 | 13.3M $ | as of Mar 31, 2026 |
| Aberdeen Group plc | 867,284 | 12.2M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 822,520 | 11.6M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 796,744 | 11.2M $ | as of Mar 31, 2026 |
| ACORN CAPITAL ADVISORS, LLC | 786,760 | 11.1M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 655,690 | 9.2M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 639,956 | 9M $ | as of Mar 31, 2026 |
| Driehaus Capital Management LLC | 635,498 | 8.9M $ | as of Mar 31, 2026 |
| RTW INVESTMENTS, LP | 573,205 | 8.1M $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 512,349 | 7.2M $ | as of Mar 31, 2026 |
| Opaleye Management Inc. | 427,608 | 6M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 402,489 | 5.7M $ | as of Mar 31, 2026 |
Declared shareholders of JADE BIOSCIENCES INC
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Fairmount Funds Management LLC and 4 others | 19.99 % | 14,069,494 | as of Jun 5, 2026 · SCHEDULE 13D |
| JANUS HENDERSON GROUP PLC | 6.30 % | 3,105,669 | as of Mar 31, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 4.70 % | 2,295,825 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding JADE BIOSCIENCES INC". https://titelia.com/en/stocks/jade-biosciences-inc-US0080642061